文献速递生殖医学

单基因病植入前遗传学检测的体外受精与自然受孕联合产前诊断用于亨廷顿病:成本效果分析

In vitro fertilization with preimplantation genetic testing for monogenetic diseases versus unassisted conception with prenatal diagnosis for Huntington disease: a cost-effectiveness analysis.
PubMed 文献 · Fertil Steril · 2022-05-23

该成本效果分析基于3,851对一方为亨廷顿病杂合子的理论队列,比较体外受精联合单基因病植入前遗传学检测与自然受孕联合产前诊断。结果显示前者成本更低且效果更高,为优势策略,可多获得77个质量调整生命年并节省46,394,268美元,且操作相关丢失、自然流产、终止妊娠及受累子代均更少。

要点

  • 在亨廷顿病杂合子夫妇中,体外受精联合植入前遗传学检测为成本效果优势策略。
  • 该策略多获得77个质量调整生命年,节省46,394,268美元。
  • 该策略减少1,079例亨廷顿病受累子代及多种妊娠不良结局。

核心结论

  • 当一方为亨廷顿病杂合子时,体外受精联合单基因病植入前遗传学检测相较于自然受孕联合产前诊断是具有成本效果的受孕策略。

研究设计与样本

  • 成本效果分析,基于3,851对一方为亨廷顿病杂合子的理论队列。
  • 支付意愿阈值设定为100,000美元/质量调整生命年。

主要发现

  • 体外受精联合植入前遗传学检测为优势策略,成本更低且效果更高。
  • 该策略多获得77个质量调整生命年,并节省46,394,268美元。
  • 该策略减少39例操作相关丢失、39例自然流产和462例终止妊娠。
  • 该策略减少1,079例亨廷顿病受累子代。
  • 结果在广泛假设范围内稳健。

关键数值与推荐

  • 支付意愿阈值为100,000美元/质量调整生命年。
  • 结局包括双亲的成本和质量调整生命年,以及操作相关丢失、自然流产、终止妊娠和早发型/经典型/晚发型亨廷顿病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate if in vitro fertilization (IVF) with preimplantation genetic testing for monogenic disease is cost effective for heterozygous individuals with Huntington disease vs. unassisted conception with prenatal diagnosis. DESIGN: Cost-effectiveness analysis in a theoretical cohort of 3,851 couples, where one individual is heterozygous for Huntington disease. SETTING: N/A. PATIENTS/ANIMALS: None. INTERVENTION: In vitro fertilization preimplantation genetic testing for couples attempting conception. MAIN OUTCOME MEASURES: Outcomes included cost and quality-adjusted life years (QALYs) for both parents in addition to secondary outcomes of procedure-related loss, spontaneous abortion, termination of pregnancy, and early/normal/late-onset Huntington disease. A willingness-to-pay threshold was set at $100,000/QALY. RESULTS: In vitro fertilization preimplantation genetic testing is lower in cost and higher in effectiveness compared to unassisted conception with prenatal diagnosis among couples with one heterozygous Huntington disease individual, making it the dominant strategy. In vitro fertilization preimplantation genetic testing was associated with 77 more QALYs and a cost savings of $46,394,268. All measured outcomes were lower in the IVF preimplantation genetic testing strategy, including 39 fewer procedure-related losses, 39 fewer spontaneous abortions, and 462 fewer terminations of pregnancy. Most notably, in our theoretical cohort of couples, IVF preimplantation genetic testing resulted in 1,079 fewer Huntington disease-affected offspring. Our results were robust over a wide range of assumptions. CONCLUSION: In vitro fertilization preimplantation genetic testing is a cost-effective conception strategy compared to unassisted conception with prenatal diagnosis when one individual is heterozygous for Huntington disease. Not only can morbidity and mortality incurred by Huntington disease be mitigated for the offspring with the use of IVF preimplantation genetic testing, but this study demonstrates the cost-effectiveness of using IVF preimplantation genetic testing for those with Huntington disease.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Christensen AA, Parker PB, Hersh AR, et al. In vitro fertilization with preimplantation genetic testing for monogenetic diseases versus unassisted conception with prenatal diagnosis for Huntington disease: a cost-effectiveness analysis. Fertil Steril. 2022. PMID: 35618525. doi:10.1016/j.fertnstert.2022.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。